speak about the value
of data sharing
SHARE For Cures is thrilled to be a part of the White House Cancer Moonshot Initiative.
Read the press release and the White House Cancer Moonshot Fact Sheet highlighting our project.
Anyone over 18 in the United States who is taking or has taken Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab) is eligible. The goal of this project is to understand the real-world impact of immunotherapy drugs on patients and to help pinpoint which patients may benefit the most from these drugs.
To participate, sign up for a SHARE account today
and use the referral code: IMMUNO
For the study, you will be asked to:
- sign up for an account with your name and email, or a Facebook or Twitter account using any referral code you received;
- consent to share your health and wellness data that you connect or input (Note: you may change your sharing preferences at any time);
- easily, automatically connect your health and wellness accounts to your SHARE account so that we can pull data from those sources;
- and, participate in the Cancer Immunotherapy Use survey (there are other optional surveys that are encouraged, but not required).
We are also collaborating with patient advocacy groups to help identify the 300 – 500 proper patients for the study who have taken a PD-1/PD-L1 inhibitor. SHARE For Cures will then work with leading researchers to analyze the data on this new class of drugs. Results of the analyses are also being returned to advocacy partners who helped with project recruitment in order to help them support patients in their communities.